gastric or gastro-oesophageal junction cancer (advanced)

Description Results NMA

OS 0.63 [0.51; 0.78] median 5.26 vs. 4.14

nivolumab at 3 mg/kg every 2 weeks (n=330)

vs.

placebo (n=163)

double blind

Parallel groups

Sample size: 330/163

Primary endpoint: OS

FU duration:

PFS 1.27 [1.03; 1.57] median 1.5 mo vs. 4.1 mo

OS 0.82 [0.66; 1.02] median 9.1 mo vs. 8.3 mo

(n=-9)

vs.

(n=-9)

Single-arm study

Sample size: -9/-9

Primary endpoint:

FU duration:

pembrolizumab (n=-9)

vs.

paclitaxel (n=-9)

open label

Sample size: -9/-9

Primary endpoint:

FU duration: